Le Lézard
Classified in: Health, Science and technology
Subject: PDT

Alleva Showcases Data-Driven EMR Platform at TCIV East 2024 Conference


PALM BEACH, Fla., May 2, 2024 /PRNewswire/ -- Alleva, a leading provider of electronic medical record (EMR) solutions, attended the first-ever East Coast TCIV conference last week in Palm Beach, Florida. The company's CEO, Steve McCall, Director of Sales, John David, and Manager of Strategic Partnerships, Shelby Nelson, were on hand to showcase Alleva's data-driven EMR platform and discuss the latest features and enhancements.

One of the highlights of the conference was Rick McKenzie's session on Scalability using Alleva's Insights tool, which was well-received by attendees. The Alleva team also received numerous questions about Alleva's EMR platform and provided valuable insights into how it can help programs leverage data to achieve better clinical outcomes and monitor team performance.

For those who missed the conference, Alleva is still readily available to answer any questions and provide information about their newly released features and enhancements. Their all-in-one tool for achieving growth has proven to be a game-changer for many organizations and treatment centers looking to streamline their processes and improve patient care.

"We are thrilled to have had the opportunity to showcase our EMR platform at the first TCIV East conference," said CEO Steve McCall. "Our team was able to connect with many professionals and provide valuable insights into how Alleva's data-driven EMR platform can help organizations achieve better outcomes and streamline their processes. We look forward to continuing to expand our reach and share the benefits of our platform with even more organizations in the future."

About Alleva

Alleva is a leading provider of electronic medical record (EMR) solutions designed to help organizations achieve better clinical outcomes and streamline their processes. Their data-driven platform provides valuable insights into team performance and patient care, helping organizations achieve growth and improve patient outcomes.

Media contact:
Sheena Streling
[email protected]

SOURCE Alleva


These press releases may also interest you

at 07:05
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Precision BioSciences, Inc. , an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today...

at 07:00
XORTX Reprices Balance of Warrants Issued in Connection with October 2021 US IPO
XORTX Therapeutics Inc. ("XORTX" or the "Company") , a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that further to its press releases of March 11 and April 30,...

at 06:18
The Week in Canadian Press Releases: 10 Stories You Need to See
With thousands of press releases published each week, it can be difficult to keep up with everything on Cision. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories...

at 05:50
NADclinic and Bontac Bio-Engineering (Shenzhen) Co., Ltd Announce Strategic Partnership to Evolve the Future of Global Wellness Through the Power of NAD+
NADclinic Group and Bontac Bio-Engineering (Shenzhen) Co., Ltd have officially entered into a dynamic strategic partnership to collaboratively focus on the future of global health and wellness. Synergistically leveraging their collective expertise...

at 05:35
Drug Farm Announces IND Clearance by U.S. FDA Enabling Phase 1b Initiation for ALPK1 Selective Kinase Inhibitor, DF-003 in ROSAH Syndrome Patients
Drug Farm announced today the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of DF-003, a first-in-class, oral, potent, highly selective alpha-kinase 1 (ALPK1) inhibitor for clinical evaluation in...

at 05:02
The Future is Now: Companion Diagnostics Market to Surge to $15.4 Billion by 2028
'Companion Diagnostics: Technologies and Markets' is all about using special tests alongside certain medicines to figure out which treatment will work best for each person. These tests are called companion diagnostics because they go together with...

More news about Health...


News published on and distributed by: